Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below Fifty Day Moving Average - Here's Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $10.44 and traded as low as $10.34. Capricor Therapeutics shares last traded at $11.42, with a volume of 2,244,716 shares trading hands.

Analysts Set New Price Targets

Several research firms recently weighed in on CAPR. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, June 24th. Roth Capital reiterated a "buy" rating and issued a $31.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Alliance Global Partners began coverage on Capricor Therapeutics in a research report on Monday, June 30th. They issued a "buy" rating and a $20.00 target price for the company. Finally, Jones Trading dropped their target price on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $32.22.

Capricor Therapeutics Price Performance

The company has a market capitalization of $520.75 million, a P/E ratio of -8.03 and a beta of 0.82. The stock has a 50-day moving average price of $10.44 and a 200-day moving average price of $12.18.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. During the same quarter last year, the business earned ($0.31) earnings per share. Sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. Farallon Capital Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $31,056,000. Vanguard Group Inc. grew its stake in Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 700,243 shares during the period. Woodline Partners LP acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $8,693,000. Octagon Capital Advisors LP acquired a new stake in Capricor Therapeutics in the first quarter valued at approximately $4,270,000. Finally, Altium Capital Management LLC grew its stake in Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after acquiring an additional 429,000 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.